公开(公告)号：US20230212139A1

公开(公告)日：2023-07-06

申请号：US18062356

申请日：2022-12-06

Applicant: NOVARTIS AG

Inventor： Amy CALHOUN ,  Xin CHEN ,  Kevin Matthew GARDINIER ,  Edward Charles HALL ,  Keith JENDZA ,  Nancy LABBE-GIGUERE ,  James NEEF ,  Daniel Steven PALACIOS ,  Ming QIAN ,  Michael David SHULTZ ,  Christopher G. THOMSON ,  Kate Yaping WANG ,  Fan YANG

IPC: C07D401/04

CPC classification number: C07D401/04 ,  A61K45/06

Abstract: Provided herein are compounds according to Formula (I)




or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.

公开(公告)号：US20220411435A1

公开(公告)日：2022-12-29

申请号：US17818321

申请日：2022-08-08

Applicant: NOVARTIS AG

Inventor： Amy CALHOUN ,  Xin CHEN ,  Kevin Matthew GARDINIER ,  Edward Charles HALL ,  Keith JENDZA ,  Nancy LABBE-GIGUERE ,  James NEEF ,  Daniel Steven PALACIOS ,  Ming QIAN ,  Michael David SHULTZ ,  Christopher G. THOMSON ,  Kate Yaping WANG ,  Fan YANG

IPC: C07D491/107 ,  A61P25/18 ,  A61K45/06

Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.

公开(公告)号：US20210130365A1

公开(公告)日：2021-05-06

申请号：US17065367

申请日：2020-10-07

Applicant: NOVARTIS AG

Inventor： Amy CALHOUN ,  Xin CHEN ,  Kevin Matthew GARDINIER ,  Edward Charles HALL ,  Keith JENDZA ,  Nancy LABBE-GIGUERE ,  James NEEF ,  Daniel Steven PALACIOS ,  Ming QIAN ,  Michael David SHULTZ ,  Christopher G. THOMSON ,  Kate Yaping WANG ,  Fan YANG

IPC: C07D491/107 ,  A61K45/06 ,  A61P25/18

Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.

公开(公告)号：US20240140959A1

公开(公告)日：2024-05-02

申请号：US18497296

申请日：2023-10-30

Applicant: NOVARTIS AG

Inventor： Amy CALHOUN ,  Xin CHEN ,  Kevin Matthew GARDINIER ,  Edward Charles HALL ,  Keith JENDZA ,  Nancy LABBE-GIGUERE ,  James Anthony NEEF ,  Daniel Steven PALACIOS ,  Ming QIAN ,  Michael David SHULTZ ,  Christopher G. THOMSON ,  Kate Yaping WANG ,  Fan YANG

IPC: C07D491/107 ,  A61K45/06 ,  A61P25/18

CPC classification number: C07D491/107 ,  A61K45/06 ,  A61P25/18

Abstract: Provided herein are compounds according to Formula (I)




or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.

公开(公告)号：US20180051015A1

公开(公告)日：2018-02-22

申请号：US15499824

申请日：2017-04-27

Applicant: NOVARTIS AG

Inventor： Thomas Raymond CAFERRO ,  Zhuoliang CHEN ,  Young Shin CHO ,  Abran Q. COSTALES ,  Julian Roy LEVELL ,  Gang LIU ,  James R. MANNING ,  Martin SENDZIK ,  Cynthia SHAFER ,  Michael David SHULTZ ,  James Clifford SUTTON ,  Yaping WANG ,  Qian ZHAO

IPC: C07D413/14 ,  C07D417/14 ,  C07D413/04 ,  A61K31/506 ,  A61K31/5377

CPC classification number: C07D413/14 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  C07D413/04 ,  C07D417/14

Abstract: The invention is directed to a formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

公开(公告)号：US20160039802A1

公开(公告)日：2016-02-11

申请号：US14774741

申请日：2014-03-13

Applicant: Young Shin CHO ,  Julian Roy LEVELL ,  Gang LIU ,  Michael David SHULTZ ,  Simon Cornelis VAN DER PLAS ,  NOVARTIS AG

Inventor： Young Shin CHO ,  Julian Roy LEVELL ,  Gang LIU ,  Michael David SHULTZ ,  Simon Cornelis VAN DER PLAS

IPC: C07D413/04 ,  C07D487/08 ,  C07D417/14 ,  A61K31/5377 ,  A61K31/506 ,  C07D413/14

CPC classification number: C07D413/04 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  C07D413/14 ,  C07D417/14 ,  C07D487/08 ,  A61K2300/00

Abstract: The invention is directed to a formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are described herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant I DH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

Abstract translation: 本发明涉及式（I）：或其药学上可接受的盐，其中R1，R2a，R2b和R3-R7如本文所述。 本发明还涉及含有式（I）化合物的组合物以及这些化合物在抑制具有新形态活性的突变体IDH蛋白质中的用途。 本发明还涉及式（I）化合物在治疗与这种突变体I DH蛋白相关的疾病或病症中的应用，包括但不限于细胞增殖病症如癌症。

公开(公告)号：US20210107889A1

公开(公告)日：2021-04-15

申请号：US17065360

申请日：2020-10-07

Applicant: NOVARTIS AG

Inventor： Amy CALHOUN ,  Xin CHEN ,  Kevin Matthew GARDINIER ,  Edward Charles HALL ,  Keith JENDZA ,  Nancy LABBE-GIGUERE ,  James NEEF ,  Daniel Steven PALACIOS ,  Ming QIAN ,  Michael David SHULTZ ,  Christopher G. THOMSON ,  Kate Yaping WANG ,  Fan YANG

IPC: C07D401/04

Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.